Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
Innocuité et efficacité du bimekizumab chez les patients atteints de rhumatisme psoriasique actif : Résultats à trois ans d'un essai contrôlé randomisé de phase IIb et de son étude de prolongation ouverte
Arthritis Rheumatol. 2022 doi: 10.1002/art.42280
This study highlighted that the safety of bimekizumab in patients with PsA over 3 years of treatment was consistent with the previous 48-week results, as well as other recently published studies of IL-17 inhibitors in PsA patients.
Keywords:
Bimekizumab chez des patients atteints de rhumatisme psoriasique actif et ayant déjà présenté une réponse inadéquate ou une intolérance aux inhibiteurs du facteur de nécrose tumorale : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo (BE COMPLETE))
Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0
This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.
Keywords:
Bimekizumab chez des patients atteints de rhumatisme psoriasique, naïfs de traitement biologique : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo (BE OPTIMAL)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9
This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.
Keywords:
Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study
Arthritis Rheumatol 2022 doi: 10.1002/art.42280
In this investigation bimekizumab was associated with a sustained ACR50 improvement. This was highlighted following the attempt to describe the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients
Keywords:
Effet du bimekizumab sur les symptômes et l'impact de la maladie chez les patients atteints de rhumatisme psoriasique sur 3 ans : Résultats de l'étude BE ACTIVE
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac353
Here bimekizumab was associated with long-term reductions in disease activity and disease impact on patients with PsA. This investigation set out to evaluate the long-term effects of bimekizumab treatment on the key symptoms of PsA and the resulting impact on patient function and HRQoL.